Overview

Trial of NanoDoce Intratumoral Injection in Renal Cell Carcinoma

Status:
Withdrawn
Trial end date:
2022-10-01
Target enrollment:
Participant gender:
Summary
This study evaluates the use of NanoDoce injected directly into tumors in the kidney of people with renal cell carcinoma.
Phase:
Phase 1
Details
Lead Sponsor:
NanOlogy, LLC
Collaborator:
US Biotest, Inc.
Treatments:
Docetaxel